In this issue:
Intensive vs minimal follow-up for recurrence in CRC
Ethnicity and treatment of rectal cancer in NZ
Surgical resection of primary tumour in advanced CRC
Individualised care optimal in rectal cancer?
Are CTX guidelines followed in rectal cancer?
Panitumumab-FOLFOX4 and RAS mutations in CRC
Irinotecan ± panitumumab in pretreated advanced CRC
FOLFOXIRI + bevacizumab in BRAF mutant mCRC
Bevacizumab + capecitabine in elderly patients with mCRC
Perioperative FOLFOX4 + surgery for resectable liver metastases
Please login below to download this issue (PDF)